Outcome | GLP-1RA | SGLT-2i | SGLT-2i vs. GLP-1RA | |||
---|---|---|---|---|---|---|
Events | Incidence rate | Events | Incidence rate | Hazard ratio, c | P-value | |
Total mortality | 145 | 8.2 (6.9–9.7) | 128 | 7.7 (6.4–9.2) | 0.78 (0.61–1.01) | 0.0641 |
MACE | 348 | 20.4 (18.3–22.7) | 392 | 24.4 (22.0–26.9) | 1.03 (0.89–1.21) | 0.6608 |
Fatal CVD | 14 | 0.8 (0.4–1.3) | 15 | 0.9 (0.5–1.5) | 1.00 (0.47–2.13) | 0.9947 |
Myocardial infarction | 82 | 4.7 (3.7–5.8) | 81 | 4.9 (3.9–6.1) | 0.94 (0.68–1.3) | 0.7295 |
Stroke | 54 | 3.1 (2.3-4.0) | 82 | 5.0 (4.0–6.2) | 1.44 (0.99–2.08) | 0.0562 |
Fatal CHF | 151 | 8.7 (7.3–10.2) | 127 | 7.7 (6.4–9.2) | 0.83 (0.65–1.07) | 0.1503 |
Renal composite | 1864 | 125.2 (119.6–131.0) | 1882 | 131.1 (125.3–137.2) | 0.98 (0.92–1.05) | 0.5676 |
30% reduction eGFR | 105 | 6 (4.9–7.3) | 87 | 5.3 (4.2–6.5) | 0.92 (0.68–1.25) | 0.5863 |
40% reduction eGFR | 56 | 3.2 (2.4–4.1) | 45 | 2.7 (2.0–3.6) | 0.94 (0.62–1.43) | 0.7718 |
Halved eGFR | 40 | 2.3 (1.6–3.1) | 28 | 1.7 (1.1–2.4) | 0.80 (0.47–1.35) | 0.4007 |
Macroalbuminuria | 403 | 23.7 (21.5–26.1) | 349 | (21.6 (19.4–24.0) | 0.89 (0.77–1.04) | 0.1408 |
Retinopathy | 9 | 0.5 (0.2–1.0) | 18 | 1.1 (0.6–1.7) | 2.15 (0.92–5.03 | 0.0784 |
Hypoglycemia | 8 | 0.5 (0.2–0.9) | 5 | 0.3 (0.1–0.7) | 0.69 (0.21–2.28) | 0.5392 |
Hyperglycemia | 9 | 0.5 (0.2-1.0) | 14 | 0.8 (0.5–1.4) | 1.88 (0.78–4.52) | 0.1571 |
Ketoacidosis | 1 | 0.1 (0.0-0.3) | 1 | 0.1 (0.0-0.3) | 1.68 (1.04–2.72) | 0.0346 |